Skip to main content
. Author manuscript; available in PMC: 2010 Dec 1.
Published in final edited form as: Clin Cancer Res. 2009 Nov 17;15(23):7299–7308. doi: 10.1158/1078-0432.CCR-09-1745

Figure 6.

Figure 6

In-vivo assessment of efficacy of various treatment groups in inhibiting VEGF expression in H1299 lung cancer xenografts models. Representative photomicrographs of VEGF expression (brown stain) using a VEGF immunohistochemistry assay in A) intravenous and B) intratumoral groups following various treatments including docetaxel, D-D, Flt23k-NP, RGD-Flt23k-NP, and D-D + RGD-Flt23k-NP. These are representative of sections in one out of 6 xenografts.